Novocure in the spotlight: Can new products offset Q3 earnings dip?

Novocure Ltd. is set to release its Q3 earnings ahead of the market open, providing a critical test for the oncology company's growth potential despite a forecasted sequential revenue decline. Analysts anticipate the medical device maker to report a loss of 23 cents per share on $182.28 million in revenue for the quarter ending September 30, representing a minor decline from the $183.6 million in the prior quarter, although revenue still managed to increase by 9.2% year-over-year.

Earnings per share (EPS) estimates have risen by 4.08% in the last 60 days, reflecting growing optimism among analysts about the company's future prospects despite the near-term challenges.

The stock currently holds a Buy rating with a mean price target of $26.86, suggesting an 84% upside potential from its current price of $14.62. Over the past year, Novocure's shares have fluctuated between $9.82 and $21.45, as the company strives to expand the use of its Tumor Treating Fields technology across various cancer indications.

The primary focus of the earnings report will be on the adoption of Optune Pax, the company's pancreatic cancer treatment. On June 30, more than 280 patients were actively using Optune Pax, following earlier approvals in the U.S., Europe, and Japan. Investors will closely monitor whether this figure continues to surge through the third quarter as new international launches commence.

Management has recently raised the 2026 revenue guidance to a range of $710 million to $725 million, following better-than-expected second-quarter results. Nonetheless, analysts anticipate a widening of sequential losses. With a 76% gross margin and 11% revenue growth in the past year, the question remains whether the company's operating leverage will start to show significant impact as the revenue base expands.

Clinical advancements will also influence investor sentiment, with the Phase 3 TRIDENT trial in glioblastoma failing to meet its primary endpoint in June, while the Phase 2 PANOVA-4 trial in metastatic pancreatic cancer demonstrated statistically significant improvements in disease control rates earlier this year. An upcoming FDA decision on the treatment of brain metastases could also serve as a potential catalyst for Novocure's stock performance.

Novocure generated $183.6 million in revenue during the second quarter, representing a 16% year-over-year increase and fueled by an 18% growth in global active patient count. The company managed to beat analyst estimates for both revenue and earnings, surprising Wall Street by 60.6% in terms of EPS as losses narrowed to 13 cents per share, compared to the anticipated 33-cent loss.

The outcome of Thursday's earnings report will determine whether Novocure can sustain this momentum or if management's confidence in raising annual guidance remains justified. The company's multi-product strategy may finally be gaining commercial traction in some of oncology's most formidable cancers, and investors will be keen to see if the current results can substantiate this optimistic outlook.